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The purpose of this study is to quantify 
antibiotic exposure for pediatric patients 
with cystic fibrosis (CF) within Lehigh Valley 
Health Network (LVHN) by characterizing the 
criteria for initiation and antibiotic regimens 
prescribed.
•  Cystic fibrosis (CF) is the most common inherited life-threatening autosomal 
recessive genetic disease that affects almost all organ systems. The most 
commonly encountered clinical presentation of CF is lung dysfunction. 
•  Pulmonary exacerbations are episodes of acute worsening of lung function 
and respiratory symptoms that are common among patients with CF. 
Treatment with antibiotics is typically initiated to preserve lung function.
  −  There is substantial variation related to when to initiate antibiotics, the 
site of treatment (inpatient versus outpatient), the antibiotic regimen 
prescribed, and duration of therapy. 
•  Antimicrobial stewardship, or optimizing the selection, dose and duration 
of antibiotic therapy, is important to attenuate or reverse antimicrobial 
resistance, prevent antimicrobial toxicities, and decrease the costs of 
inappropriate antimicrobial use and healthcare associated infections. 
•  Due to the lack of standardized recommendations for antibiotic 
management for pulmonary exacerbations in patients with CF, we aim to 
characterize the antibiotic regimens across the inpatient and outpatient 
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•  Retrospective chart review of pediatric patients with CF within LVHN. 
•  INCLUSION CRITERIA  
  −  Patients younger than 25 years of age with a confirmed diagnosis of CF 
being followed by pediatric pulmonology at LVHN
  −  Patient received antibiotic therapy (outpatient and/or inpatient) for a 
pulmonary exacerbation, as diagnosed by a pediatric pulmonologist, during 
the study period
•  EXCLUSION CRITERIA  
  −  Primary diagnosis for treatment with antibiotics unrelated to a pulmonary 
exacerbation 
  −  Patients presenting with massive hemoptysis, as defined and documented 
by pediatric pulmonologist 
•  The primary objective of this study will be to calculate the median days of 
antibiotic therapy in patients with CF.  
•  Secondary objectives
  −  Determine the rate of days of antibiotic therapy per patient during the study 
period
  −  Characterize the criteria for initiation based on clinical signs and symptoms 
versus clinical decline as defined by change in FEV1 % predicted
  −  Calculate the duration of antibiotic courses of inpatient and outpatient 
therapy
    •  Evaluate durations of therapy based on gender, genotype, weight status, 
history of exposure to various pathogens, FEV1 < 75% predicted, presence 
of CF-related complications, receipt 
of chronic medication therapy, 
duration of symptoms prior to 
treatment initiation, and presence of 
symptoms
    •  Calculate time between antibiotic 
courses
•  LVHN’s pediatric pulmonary CF database will be used to identify patients with 
a documented CF exacerbation for which he/she received antibiotics from     
August 1, 2015 to July 31, 2017. Inpatient and outpatient electronic medical 
records will be reviewed.
•  Data to be collected will include:
  − Patient age, gender, height, weight, race, CF genotype
  −  Hospitalizations in the previous 12 months, respiratory microbiology within 
the previous 12 months, chronic medications prescribed, presence of CF-
related complications
  −  Per each pulmonary exacerbation, the following will be collected:
    •  BMI/weight percentile for age compared to previous best, spirometry, 
characterization of symptoms, documentation of therapy goal
    •  Antibiotic regimen: name of antibiotic, antibiotic class, route, start/
discontinuation dates, initiation via office visit vs. phone call
    •  Admission/discharge date, PICC line placement, duration of OPAT 
(outpatient antibiotic therapy) will be collected, if applicable:
•  Total antibiotic days will be calculated per patient and the median will be 
reported for the group as a whole. A rate of antibiotic therapy will also be 
reported per patient to quantify individual antibiotic exposure. Statistical analysis 
will be conducted to determine if any statistically significant differences exist in 
antibiotic days for predefined patient groups.
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